Verastem, Inc.

Equities

VSTM

US92337C2035

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 31/05/2024 BST			5-day change	1st Jan Change
3.96 ^USD	-0.75%		-67.49%	-51.35%

05-28	RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier	MT
05-24	Top Midday Decliners	MT

Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 09, 2023 at 09:18 pm

Verastem, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 15.71 million compared to USD 16.96 million a year ago. Basic loss per share from continuing operations was USD 0.96 compared to USD 1.08 a year ago.

Diluted loss per share from continuing operations was USD 0.96 compared to USD 1.08 a year ago.

Latest news about Verastem, Inc.

RBC Halves Price Target on Verastem to $16 From $32, Maintains Outperform Rating, Speculative Risk Qualifier	05-28	MT
Top Midday Decliners	05-24	MT
Sector Update: Health Care Stocks Advance Pre-Bell Friday	05-24	MT
Verastem Reports Results of Potential Pancreatic Cancer Treatment, Submits Rolling New Drug Application for Rare Ovarian Cancer	05-24	MT
Transcript : Verastem, Inc. - Special Call	05-24
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer	05-23	CI
Verastem, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Verastem Names John Hayslip as Chief Medical Officer	04-18	MT
Verastem Oncology Announces Executive Changes	04-18	CI
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-14	CI
Verastem Oncology's Ovarian Cancer Drug Gets FDA Orphan Drug Designation	03-05	DJ
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer	03-05	MT
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers	01-29	CI
Sector Update: Health Care Stocks Mixed Premarket Friday	01-19	MT
Sector Update: Health Care	01-19	MT
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer	01-18	MT
Verastem Gets FDA Fast-Track Approval on Lung Cancer Treatment	01-18	DJ
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics	12-18	CI
Verastem Starts Confirmatory Trial of Ovarian Cancer Treatment Candidate	12-13	MT
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	12-13	CI
Truist Securities Cuts Price Target on Verastem to $34 From $39, Maintains Buy Rating	11-15	MT
Verastem Oncology Announces the Launch of the New Healthcare Professional Component	11-13	CI
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08	CI
Verastem Promotes Vice President of Finance Dan Calkins to CFO	27/10/23	MT

Chart Verastem, Inc.

Duration

Period

More charts

Company Profile

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company's pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Companyâs advanced product candidates, avutometinib and defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), pancreatic cancer, colorectal cancer (CRC), and melanoma. Avutometinib is an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma (RAS)/RAF/MEK, ERK mitogen activated pathway kinase (MAPK) pathway. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2).

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - ASCO Meeting - Abstract Number: 4140

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.96 USD

Average target price

22.5 USD

Spread / Average Target

+468.18%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERASTEM, INC.	-51.35%	101M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	114B
REGENERON PHARMACEUTICALS, INC.	+11.60%	105B
BIONTECH SE	-4.68%	23.83B
ARGENX SE	-0.82%	21.73B
GENMAB A/S	-10.12%	18.1B
WUXI APPTEC CO., LTD.	-42.12%	16.34B
BEIGENE, LTD.	-17.47%	16.13B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.75B
SAREPTA THERAPEUTICS, INC.	+34.58%	11.76B

Bio Therapeutic Drugs